Insider · CIK 0001582393
Anthony P. Zook
Files at NEO (NEOGENOMICS INC), APTN (ADAPTIN BIO, INC.). First filing May 8, 2025, latest Aug 6, 2025.
In brief
Anthony P. Zook files SEC Form 4 as CEO and director at NEO (NEOGENOMICS INC), and also at APTN (ADAPTIN BIO, INC.). Since May 8, 2025, Anthony P. Zook has reported 2 open-market buys worth $249k and 0 open-market sells worth $0, the latest filed on Aug 6, 2025.
A track record needs three past buys with six months of prices behind them; Anthony P. Zook has 0, so none is measured yet.
The newest scored trade: bought $100k of NEO on Aug 6, 2025, filed Aug 6, 2025, scored 61 (notable).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NEO: NEOGENOMICS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 61Notable | NEOGENOMICS INC | $100k 17,900 shares | +89% | +13% from low-71% from high | |
| 67Notable | NEOGENOMICS INC | $149k 18,900 shares | - | +20% from low-59% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | NEO NEOGENOMICS INC | MOption exercise Common Stock | +140,498 | $0.00 | $0 | 178,564 | Apr 3, 2026 |
| Apr 1, 2026 | NEO NEOGENOMICS INC | FTax withholding Common Stock | -45,453 | $0.00 | $0 | 133,111 | Apr 3, 2026 |
| Apr 1, 2026 | NEO NEOGENOMICS INC | MOption exercise Restricted Stock Unitderivative | -140,498 | $0.00 | $0 | 280,998 | Apr 3, 2026 |
| Mar 1, 2026 | NEO NEOGENOMICS INC | AGrant or award Stock Option (Right to Buy)derivative | +675,676 | $0.00 | $0 | 675,676 | Mar 3, 2026 |
| Mar 1, 2026 | NEO NEOGENOMICS INC | AGrant or award Restricted Stock Unitderivative | +406,918 | $0.00 | $0 | 406,918 | Mar 3, 2026 |
| Sep 8, 2025 | APTN ADAPTIN BIO, INC. | AGrant or award Stock Option (right to buy)derivative | +109,847 | $0.00 | $0 | 109,847 | Sep 10, 2025 |
| Aug 6, 2025 | NEO NEOGENOMICS INC | POpen-market purchase Common Stock | +17,900 | $5.58 | $100k | 38,066 | Aug 6, 2025 |
| Jun 1, 2025 | NEO NEOGENOMICS INC | MOption exercise Common Stock | +12,254 | $0.00 | $0 | 23,590 | Jun 3, 2025 |
| Jun 1, 2025 | NEO NEOGENOMICS INC | FTax withholding Common Stock | -3,424 | $0.00 | $0 | 20,166 | Jun 3, 2025 |
| Jun 1, 2025 | NEO NEOGENOMICS INC | MOption exercise Restricted Stock Unitderivative | -12,254 | $0.00 | $0 | 0 | Jun 3, 2025 |
| May 6, 2025 | NEO NEOGENOMICS INC | POpen-market purchase Common Stockindirect: Amended and Restated Anthony P. Zook Living Trust | +18,900 | $7.88 | $149k | 18,900 | May 8, 2025 |
| Apr 1, 2025 | NEO NEOGENOMICS INC | AGrant or award Stock Option (Right to Buy)derivative | +729,927 | $0.00 | $0 | 729,927 | Apr 3, 2025 |
| Apr 1, 2025 | NEO NEOGENOMICS INC | AGrant or award Restricted Stock Unitderivative | +421,496 | $0.00 | $0 | 421,496 | Apr 3, 2025 |
Questions about Anthony P. Zook
Answered from the filings on this page, as of the latest one.
Is Anthony P. Zook buying or selling?
Not in the last 12 months. Anthony P. Zook's latest open-market trade on SEC Form 4 was bought $100k of NEO on Aug 6, 2025.
How did Anthony P. Zook's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Anthony P. Zook has 0.
Where does Anthony P. Zook file Form 4?
Anthony P. Zook has filed Form 4 at NEO (NEOGENOMICS INC) as Chief Executive Officer; APTN (ADAPTIN BIO, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.